ROCHE HOLDING AG ' KEYSTONE / GEORGIOS KEFALAS
, source
Switzerland Roche
March 14, 2023 at 07:17 am
Share
Share
© Acquiremedia - 2023
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 252.8 CHF | +1.12% |
|
+2.10% | +3.39% |
| 06-21 | US FDA approves Roche's drug for a chronic blood disorder | RE |
| 06-21 | Nykredit Bank Initiates Coverage on Roche With Buy Recommendation | MT |
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250
CHF
Average target price
278.1
CHF
Spread / Average Target
+11.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.39% | 227B | |
| +51.63% | 798B | |
| +41.51% | 633B | |
| -5.10% | 356B | |
| +19.90% | 328B | |
| +9.95% | 304B | |
| +17.66% | 244B | |
| +10.75% | 216B | |
| +6.99% | 166B | |
| -3.65% | 157B |
- Stock Market
- Equities
- ROG Stock
- News Roche Holding AG
- Switzerland Roche
